GlassScriptPhysician profile
Raymon Kumar Aggarwal
NPI 1821007279
$15,676.52
in general payments reported to CMS, 2019-2025
52 companies · $3,434 in 2025
The $3,434 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $593 · 2021: $1,355 · 2022: $687 · 2023: $1,209 · 2024: $6,351 · 2025: $3,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,779 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,180 · Travel and Lodging: $34.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,779.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,180.00 |
| Travel and Lodging | $34.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,699.69 | 2019-2025 | Repatha, Repatha, Evenity |
| Amarin Pharma, INC. | $871.26 | 2019-2023 | |
| Novo Nordisk INC | $764.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Atricure, INC. | $720.56 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Siemens Medical Solutions USA, INC. | $628.19 | 2023-2024 | Somatom Go.Top, Magnetom Free.Max |
| Abbott Laboratories | $592.80 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $522.66 | 2019-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $489.52 | 2019-2025 | |
| Lilly USA, LLC | $470.08 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Itamar Medical INC | $390.58 | 2022-2025 | Watchpatone |
| Pfizer INC. | $370.86 | 2019-2025 | |
| Abbvie INC. | $361.18 | 2019-2024 | Ubrelvy, Qulipta |
| Sanofi-Aventis U.S. LLC | $322.59 | 2019-2025 | |
| Astellas Pharma US INC | $314.28 | 2019-2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $302.80 | 2019-2024 | Eliquis, Camzyos |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymon Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.